But in an Arena study published online this week in the journal Circulation: Cardiovascular Imaging, evaluation of over 5, 200 patients in phase 3 trials of 52 weeks of lorcaserin (10 mg, twice daily) or placebo showed only a slight difference in heart valve problems: 2.04% for placebo and 2.37% for lorcaserin.